GreenGro Technologies Announces Launch of New Hemp Infused Product Line Under GreenGro Brand
Anaheim–GreenGro Technologies, Inc. (OTC: GRNH), an established provider of eco-friendly green technologies for the industrial hemp and cannabis industries, today announced the launch of its highly anticipated product line of hemp infused tinctures, topicals, oil and capsules.
The Company also announced that it has entered into two new distribution agreements with a network of pain management clinics, pharmacies and dispensaries to immediately begin marketing and selling its new product line.
This initial launch will focus on the Company’s line of hemp-infused products which do not contain tetrahydrocannabinol (THC), the main psychoactive component found in cannabis. These high-quality formulations will continue to also be available online at https://greengrotech.com/shop/ as the Company focuses on building its market presence through the expansion of its distribution network across the nation.
“We are excited to offer consumers new and innovative hemp-infused products across a variety of delivery methods,” said Tom Schaefer, Chief Executive Officer of CBD Ventures, a wholly owned subsidiary of GreenGro Technologies, Inc. “Our new product line will be available across a network of independent retailers in California and Arizona and help drive future revenue growth while building GreenGro’s brand recognition.”
(Safe Harbor Act: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve several risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.)
Reunion Neuroscience to be Acquired by MPM BioImpact in $13.1 Million All-Cash Deal
LOS ANGELES-- Reunion Neuroscience Inc. a clinical-stage biopharmaceutical company specializing in innovative therapies for underserved mental health conditions, has announced a definitive arrangement agreement with MPM BioImpact, a leading biotechnology investment firm. Under the agreement, ...
California’s Regulated Cannabis Market Sees Decline in Sales and Tax Revenue in Q1 2023
LOS ANGELES-- California's hopes of increased consumer participation in the regulated cannabis market did not translate into a boost in licensed retail sales or state tax revenue during the first quarter of 2023. According to ...
C21 Investments Repays $30 Million Debt to CEO Sonny Newman
LOS ANGELES-- C21 Investments Inc., a vertically integrated cannabis company, announced today the successful completion of the full repayment of its $30 million senior secured note owed to Sonny Newman, the Company's President and Chief ...